{
  "source": "PA-Med-Nec-Tremfya.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2206-10\nProgram Prior Authorization/Medical Necessity\nMedication *Tremfya® (guselkumab)\n*This program applies to the subcutaneous formulations of Tremfya\nP&T Approval Date 5/2020, 11/2020, 6/2021, 12/2021, 12/2022, 3/2023, 7/2023, 10/2024,\n11/2024, 3/2025\nEffective Date 5/1/2025\n1. Background:\nTremfya (guselkumab) is an interleukin-23 blocker indicated for the treatment of adult\npatients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or\nphototherapy, active psoriatic arthritis, moderately to severely active ulcerative colitis, and\nmoderately to severely active Crohn’s disease.\n2. Coverage Criteriaa:\nA. Plaque Psoriasis\n1. Initial Authorization\na. Tremfya will be approved based on all of the following criteria:\n(1) Diagnosis of moderate to severe plaque psoriasis\n-AND-\n(2) One of the following:\n(a) All of the following:\ni. Greater than or equal to 3% body surface area involvement, palmoplantar,\nfacial, genital involvement, or severe scalp psoriasis\n-AND-\nii. History of failure to one of the following topical therapies, unless\ncontraindicated or clinically significant adverse effects are experienced\n(document drug, date, and duration of trial):\na. Corticosteroids (e.g., betamethasone, clobetasol, desonide)\nb. Vitamin D analogs (e.g., calcitriol, calcipotriene)\nc. Tazarotene\nd. Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)\ne. Anthralin\nf. Coal tar\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND-\niii. History of failure to a 3 month trial of methotrexate at maximally\nindicated dose, unless contraindicated or clinically significant adverse\neffects are experienced (document date and duration of trial)b\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of plaque psoriasis as documented by claims\nhistory or submission of medical records (Document drug, date, and duration\nof therapy) [e.g., Cimzia (cer",
    "d immunomodulator FDA-\napproved for the treatment of plaque psoriasis as documented by claims\nhistory or submission of medical records (Document drug, date, and duration\nof therapy) [e.g., Cimzia (certolizumab), adalimumab, Otezla (apremilast),\nSkyrizi (risankizumab), ustekinumab].\n-OR-\n(c) Both of the following:\ni. Patient is currently on Tremfya therapy as documented by claims history or\nsubmission of medical records (Document date and duration of therapy)\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in\nthe prescriber’s office, or any form of assistance from the Janssen\nsponsored CarePath Savings program (e.g., sample card which can be\nredeemed at a pharmacy for a free supply of medication) as a means to\nestablish as a current user of Tremfya*\n-AND-\n(3) Patient is not receiving Tremfya in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi\n(risankizumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq\n(brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\n-AND-\n(4) Prescribed by or in consultation with a dermatologist\n* Patients requesting initial authorization who were established on therapy via the receipt\nof a manufacturer supplied sample at no cost in the prescriber’s office or any form of\nassistance from the Janssen sponsored CarePath Savings program shall be required to\nmeet initial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n2\n2. Reauthorization\na. Tremfya will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Tremfya therapy\n-AND-\n(2) Patient is not receiving Tremfya in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(go",
    "tive clinical response to Tremfya therapy\n-AND-\n(2) Patient is not receiving Tremfya in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi\n(risankizumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq\n(brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\nB. Psoriatic Arthritis (PsA)\n1. Initial Authorization\na. Tremfya will be approved based on all of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) One of the following:\n(a) History of failure to a 3 month trial of methotrexate at the maximally indicated\ndose, unless contraindicated or clinically significant adverse effects are\nexperienced (document date and duration of trial)b\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of psoriatic arthritis as documented by claims\nhistory or submission of medical records (Document drug, date, and duration\nof therapy) [e.g., Cimzia (certolizumab), adalimumab, Simponi (golimumab),\nustekinumab, Xeljanz (tofacitinib), Otezla (apremilast), Rinvoq\n(upadacitinib)].\n-OR-\n(c) Both of the following:\ni. Patient is currently on Tremfya therapy as documented by claims history or\nsubmission of medical records (Document date and duration of therapy)\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n3\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Janssen sponsored\nCarePath Savings program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Tremfya*\n-AND-\n(3) Patient is not receiving Tremfya in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi",
    "ns to establish as a\ncurrent user of Tremfya*\n-AND-\n(3) Patient is not receiving Tremfya in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi\n(risankizumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\n-AND-\n(4) Prescribed by or in consultation with one of the following:\n(a) Rheumatologist\n(b) Dermatologist\n* Patients requesting initial authorization who were established on therapy via the receipt\nof a manufacturer supplied sample at no cost in the prescriber’s office or any form of\nassistance from the Janssen sponsored CarePath Savings program shall be required to\nmeet initial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tremfya will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Tremfya therapy\n-AND-\n(2) Patient is not receiving Tremfya in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi\n(risankizumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\nAuthorization will be issued for 12 months.\nC. Ulcerative Colitis (UC)\n1. Initial Authorization for Maintenance Dosing\n© 2025 UnitedHealthcare Services, Inc.\n4\na. Tremfya will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active ulcerative colitis\n-AND-\n(2) One of the following:\n(a) Patient has been established on therapy with Tremfya under an active\nUnitedHealthcare medical benefit prior authorization for the treatment of\nmoderately to severely active ulcerative colitis\n-OR-\n(b) Both of the following:\ni. Patient is c",
    " with Tremfya under an active\nUnitedHealthcare medical benefit prior authorization for the treatment of\nmoderately to severely active ulcerative colitis\n-OR-\n(b) Both of the following:\ni. Patient is currently on Tremfya therapy for moderately to severely active\nulcerative colitis as documented by claims history or submission of\nmedical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Janssen sponsored\nCarePath Savings program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Tremfya*\n-AND-\n(3) Patient is not receiving Tremfya in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib), ustekinumab, adalimumab, Skyrizi\n(risankizumab)]\n-AND-\n(4) Prescribed by or in consultation with a gastroenterologist\n* Patients requesting initial authorization who were established on therapy via the receipt\nof a manufacturer supplied sample at no cost in the prescriber’s office or any form of\nassistance from the Janssen sponsored CarePath Savings program shall be required to\nmeet initial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tremfya will be approved based on both of the following criteria:\n© 2025 UnitedHealthcare Services, Inc.\n5\n(1) Documentation of positive clinical response to Tremfya therapy\n-AND-\n(2) Patient is not receiving Tremfya in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib), ustekinumab, adalimumab, Skyrizi\n(risankizumab)]\nAuthorization will be issued ",
    "lizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib), ustekinumab, adalimumab, Skyrizi\n(risankizumab)]\nAuthorization will be issued for 12 months.\nD. Crohn’s Disease (CD)\n1. Initial Authorization\na. Tremfya will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active Crohn’s disease\n-AND-\n(2) One of the following:\n(a) Patient has been established on therapy with Tremfya under an active\nUnitedHealthcare medical benefit prior authorization for the treatment of\nmoderately to severely active Crohn’s disease\n-OR-\n(b) One of the following:\ni. History of failure to one of the following conventional therapies at up to\nmaximally indicated doses, unless contraindicated or clinically significant\nadverse effects are experienced (document drug, date, and duration of\ntrial):\n• Corticosteroids (e.g., prednisone, methylprednisolone, budesonide)\n• 6-mercaptopurine (Purinethol)\n• Azathioprine (Imuran)\n• Methotrexate (Rheumatrex, Trexall)\n-OR-\nii. Patient has been previously treated with a targeted immunomodulator\nFDA-approved for the treatment of Crohn’s disease as documented by\nclaims history or submission of medical records (Document drug, date, and\nduration of therapy) [e.g., adalimumab, Cimzia (certolizumab), Entyvio\n(vedolizumab), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib),\nSkyrizi (risankizumab), ustekinumab]\n© 2025 UnitedHealthcare Services, Inc.\n6\n-OR-\n(c) Both of the following:\ni. Patient is currently on Tremfya therapy for moderately to severely active\nCrohn’s disease as documented by claims history or submission of medical\nrecords (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Janssen sponsored\nCarePath Savings program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establis",
    "r’s office, or any form of assistance from the Janssen sponsored\nCarePath Savings program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Tremfya*\n-AND-\n(3) Patient is not receiving Tremfya in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Entyvio\n(vedolizumab), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Skyrizi\n(risankizumab), ustekinumab]\n-AND-\n(4) Prescribed by or in consultation with a gastroenterologist\n* Patients requesting initial authorization who were established on therapy via the receipt\nof a manufacturer supplied sample at no cost in the prescriber’s office or any form of\nassistance from the Janssen sponsored CarePath Savings program shall be required to\nmeet initial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Tremfya will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Tremfya therapy\n-AND-\n(2) Patient is not receiving Tremfya in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Entyvio\n(vedolizumab), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Skyrizi\n(risankizumab), ustekinumab]\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n7\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by progr",
    "pprove initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. Reference:\n1. Tremfya [package insert]. Horsham, PA: Janssen Biotech Inc.; September 2024.\n2. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis\nand psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment\nof psoriasis with biologics. J Am Acad Dermatol 2008; 58(5):826-50.\n3. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis\nand psoriatic arthritis. Psoriatic arthritis: Overview and guidelines of care for treatment with\nan emphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64.\n4. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis\nand psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of\npsoriasis with topical therapies. J Am Acad Dermatol 2009;60(4):643-59.\n5. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis\nand psoriatic arthritis. Guidelines of care for the treatment of psoriasis with phototherapy and\nphotochemotherapy. J Am Acad Dermatol 2010;62(1):114-35.\n6. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis\nand psoriatic arthritis. Guidelines of care for the management and treatment of psoriasis with\ntraditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85.\n7. Nast A, et al; European S3-Guidelines on the systemic treatment of psoriasis vulgaris – update\n2015 – short version – EFF in cooperation with EADV and IPC, J Eur Acad Derm Venereol\n2015;29:2277-94.\n8. Menter A, Korman NJ, Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care\nfor the management of psoriasis and psoriatic arthritis: section 6. Guideli",
    " Acad Derm Venereol\n2015;29:2277-94.\n8. Menter A, Korman NJ, Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care\nfor the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the\ntreatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based\nconclusions. J Am Acad Dermatol. 2011 Jul;65(1):137-74.\n9. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the\nmanagement and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-\n72.\nProgram Prior Authorization/Medical Necessity - Tremfya (guselkumab)\nChange Control\n5/2020 New program\n11/2020 Added review criteria for psoriatic arthritis due to new indication.\nUpdated background and references.\n6/2021 Removed preceding month requirement from failure criteria. Added\ncoverage criteria for patients previously treated with a biologic\n© 2025 UnitedHealthcare Services, Inc.\n8\nDMARD. Removed prescriber requirement from reauthorization\ncriteria. Added clarification that submission of medical records is\nrequired documenting previous or current therapy with a biologic\nDMARD in order to bypass step through non-biologic therapies if claim\nhistory not available.\n12/2021 Updated conventional DMARD bypass language for psoriasis and\npsoriatic arthritis with no change to clinical intent. Updated CT/KY\nfootnote.\n12/2022 Annual review with no change to clinical criteria. Added Rinvoq as an\nexample where appropriate.\n3/2023 Updated state mandate footnote to include Mississippi. Updated\nexamples to adalimumab.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n10/2024 Annual review with no changes to coverage criteria. Updated state\nmandate footnote and reference.\n11/2024 Added coverage criteria for ulcerative colitis. Updated background and\nreference.\n3/2025 Added coverage criteria for ulcerative colitis. Updated background.\n© 2025 UnitedHealthcare Services, Inc.\n9"
  ]
}